Medtronic InFuse Bone Graft Is “Approvable” For Oral Use – FDA Dental Panel
This article was originally published in The Gray Sheet
Executive Summary
A possible reduction in morbidity associated with use of Medtronic's InFuse bone graft compared with conventional autograft treatment for oromaxillofacial bone defects outweighs potentially reduced efficacy of up to 20% and justifies FDA approval, the agency's Dental Products Panel agreed Nov. 9
You may also be interested in...
Approvals Get Medtronic Into Dental And Pediatric Diabetes Markets
Medtronic will soon take its first steps into both the dental market and the pediatric glucose monitor market
Approvals Get Medtronic Into Dental And Pediatric Diabetes Markets
Medtronic will soon take its first steps into both the dental market and the pediatric glucose monitor market
Medtronic Loses ICD Market Share, Looks Ahead To U.S. Market Rebound
Medtronic is optimistic about a recovery in the implantable cardioverter defibrillator market, despite lower-than-expected sales in its most recent fiscal quarter, reported Feb. 20